Shopping Cart
- Remove All
Your shopping cart is currently empty
BAY 87-2243 is a potent and selective inhibitor of hypoxia-inducible factor-1 (HIF-1).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $30 | In Stock | |
| 2 mg | $38 | In Stock | |
| 5 mg | $60 | In Stock | |
| 10 mg | $109 | In Stock | |
| 25 mg | $235 | In Stock | |
| 50 mg | $389 | In Stock | |
| 100 mg | $652 | In Stock | |
| 200 mg | $913 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $70 | In Stock |
| Description | BAY 87-2243 is a potent and selective inhibitor of hypoxia-inducible factor-1 (HIF-1). |
| In vitro | BAY87-2243 (administered orally at 4 mg/kg) reduced tumor weight, HIF-1α protein, and HIF-1 target gene expression levels in an H460 xenograft mouse model. |
| In vivo | In hypoxic lung cancer H460 cells, BAY 87-2243 inhibits the expression of HIF target genes and suppresses the accumulation of HIF-1α protein. It impairs cell proliferation by interfering with mitochondrial function under glucose consumption. Additionally, BAY 87-2243 inhibits the reporter gene activity of HIF-1 and the expression of CA9 protein, with IC50 values of 0.7 nM and 2 nM, respectively. |
| Cell Research | To evaluate the cytotoxicity of BAY 87-2243, 2.000 cells of the respective cell lines are seeded in 96-well plates and cultured in the appropriate growth medium containing 10% FCS. BAY 87-2243 at various concentrations is added at 24 h after seeding for additional 48 h and cell viability is determined using Cell Titer Glow Assay.(Only for Reference) |
| Molecular Weight | 525.53 |
| Formula | C26H26F3N7O2 |
| Cas No. | 1227158-85-1 |
| Smiles | Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1 |
| Relative Density. | 1.47 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 52.55 mg/mL (100 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.